Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in pat... Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. Show more
Aileron Therapeutics to Present at the 8th Annual IPF Summit PR Newswire AUSTIN, Texas, Aug. 19, 2024 AUSTIN, Texas, Aug. 19, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:...
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights PR Newswire AUSTIN, Texas, Aug. 14, 2024 Announced positive data from Cohort 1 of the ongoing Phase 1b...
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference PR Newswire AUSTIN, Texas, July 30, 2024 AUSTIN, Texas, July 30, 2024 /PRNewswire/ -- Aileron Therapeutics...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.22 | -7.66550522648 | 2.87 | 2.91 | 2.65 | 68401 | 2.85006538 | CS |
4 | 0.05 | 1.92307692308 | 2.6 | 2.93 | 2.2 | 40492 | 2.71448969 | CS |
12 | -0.3 | -10.1694915254 | 2.95 | 3.3 | 1.61 | 54040 | 2.61639013 | CS |
26 | -2.69 | -50.3745318352 | 5.34 | 7.42 | 1.61 | 81482 | 3.84244301 | CS |
52 | 1.08 | 68.7898089172 | 1.57 | 7.42 | 1.01 | 79727 | 3.67151331 | CS |
156 | -18.75 | -87.6168224299 | 21.4 | 22.4 | 1.01 | 256347 | 7.33210311 | CS |
260 | -16.352 | -86.0540995685 | 19.002 | 49.4 | 1.01 | 612282 | 22.9044318 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.